Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Maiyue He"'
Autor:
Mingxia Jiang, Yue Chai, Jiaxuan Liu, Maiyue He, Yipeng Wang, Xue Yang, Zeyu Xing, Mengqi Zhang, Shihan Zhou, Fei Ma, Jiayu Wang, Peng Yuan, Binghe Xu, Qiao Li
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Inetetamab is the first domestically developed innovative anti-HER2 monoclonal antibody in China, proven effective and safe in HER2-positive advanced breast cancer. However, its efficacy and safety in neoadjuvant treatment of HER2
Externí odkaz:
https://doaj.org/article/32387e293c134642a179a5d28b93fb22
Autor:
Mingxia Jiang, Jiaxuan Liu, Maiyue He, Mengqi Zhang, Shihan Zhou, Shanshan Chen, Ruigang Cai, Hongnan Mo, Bo Lan, Pin Zhang, Binghe Xu, Qiao Li
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Inetetamab is a novel antibody targeting human epidermal growth factor receptor 2 (HER2) developed in China. Due to its optimized antibody-dependent cell-mediated cytotoxicity effect compared with trastuzumab, it has shown good efficacy a
Externí odkaz:
https://doaj.org/article/84df8beb4c8646e5827cc01f438d0280
Publikováno v:
Thoracic Cancer, Vol 14, Iss 27, Pp 2793-2803 (2023)
Abstract Background The aim of this study was to investigate epidemiological characteristics, risk factors, optimal treatment options, and survival outcomes of breast cancer patients with isolated liver metastasis (BCILM). Methods Patients with breas
Externí odkaz:
https://doaj.org/article/7d2a6806343341b2af21ea78a9fdac59
Autor:
Yue Chai, Jiaxuan Liu, Mingxia Jiang, Maiyue He, Zijing Wang, Fei Ma, Jiayu Wang, Peng Yuan, Yang Luo, Binghe Xu, Qiao Li
Publikováno v:
Thoracic Cancer, Vol 14, Iss 23, Pp 2259-2268 (2023)
Abstract Background This single‐arm prospective phase II trial was performed to assess the efficacy and safety of the dual oral metronomic vinorelbine and capecitabine (mNC) regimen in women with HER2‐negative metastatic breast cancer (MBC) in Ch
Externí odkaz:
https://doaj.org/article/248637297f8d443e881673fe2afe1409
Autor:
Maiyue He, Jiaxuan Liu, Zijing Wang, Fei Ma, Jiayu Wang, Pin Zhang, Qing Li, Peng Yuan, Yang Luo, Ying Fan, Hongnan Mo, Bo Lan, Qiao Li, Binghe Xu
Publikováno v:
Breast, Vol 72, Iss , Pp 103581- (2023)
Purpose: To analyze the safety and efficacy of orally administered metronomic capecitabine plus pyrotinib in HER2 positive metastatic breast cancer (MBC) patients, we conducted a prospective phase II study with a single-arm design. Methods: HER2 posi
Externí odkaz:
https://doaj.org/article/a524b5a0f6d3492f8e77b1430648f736
Autor:
Mingxia Jiang, Bin Shao, Donggui Wan, Jiaxuan Liu, Maiyue He, Yue Chai, Die Sang, Jiayu Wang, Fei Ma, Ying Fan, Peng Yuan, Binghe Xu, Qiao Li
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: The relative lack of specifically targeted agents for HER2-negative metastatic breast cancer (MBC) makes the need for new agents or combination therapies to maximize clinical benefit while reducing toxicity critical. Objectives: To retros
Externí odkaz:
https://doaj.org/article/026cae5a95ff4e2f957b926638e06a4e
Autor:
Juanjuan Hu, Haiyang Wang, Jianli Chen, Xuelin Pan, Di Deng, Lufang Zhuo, Shixi Liu, Maiyue He, Fei Chen, Hui Yang
Publikováno v:
BMC Surgery, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Subglottic paragangliomas (PGs) are exceptionally rare and unpredictable, occasionally presenting at an atypical location. There are three different clinical forms of subglottic PGs: intraluminal (tracheal PGs), extraluminal (thyr
Externí odkaz:
https://doaj.org/article/897c152406b547f795a0cb8a71763ed5
Autor:
Hui Yang, Juanjuan Hu, Di Deng, Jianli Chen, Shixi Liu, Fei Chen, Lufang Zhuo, Haiyang Wang, Xuelin Pan, Maiyue He
Publikováno v:
BMC Surgery, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Surgery
BMC Surgery
Background Subglottic paragangliomas (PGs) are exceptionally rare and unpredictable, occasionally presenting at an atypical location. There are three different clinical forms of subglottic PGs: intraluminal (tracheal PGs), extraluminal (thyroid PGs)
Publikováno v:
Oncology research and treatment. 45(11)
Background: Metronomic chemotherapy (MCT), termed sustained low-dose administration with minimal toxicity, is a new modality of conventional chemotherapy, a verified therapy alternative, and has acquired significant recognition and interest in oncolo
Publikováno v:
Journal of the Neurological Sciences. 399:155-160
Background Hematoma enlargement happens in about 30% patients with intracerebral hemorrhage, which is reported to be closely correlated with poor prognosis. Swirl sign has been reported to have correlation with hematoma enlargement. This meta-analysi